Phase I/IIa trial in advanced pancreatic ductal adenocarcinoma treated with cytotoxic drug-packaged, EGFR-targeted nanocells and glycolipid-packaged nanocells.

Vinod GanjuGavin MarxScott PattisonNancy B Amaro-MugridgeJing-Ting ZhaoBryan R G WilliamsJennifer A MacDiarmidHimanshu Brahmbhatt
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
E-EDV-D682/GC provided significant OS, minimal side effects and weight stabilization in advanced PDAC patients. Advanced PDAC can be safely treated with super-cytotoxic drugs via EDVs to overcome multi-drug resistance.